Skip to content
TrialScanner

NCT01617629

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

Phase 2CompletedIMMPLead

Registry record

Lead sponsor
Prima BioMed Ltd
Conditions
Epithelial Ovarian Cancer
Primary completion
Apr 2014Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01617629 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01617629: Ovarian Cancer Vaccine for... | TrialScanner